衡阳市成功治疗的肺结核患者5年复发影响因素分析

doi:10.19485/j.cnki.issn2096-5087.2022.03.011

预防医学

2022, Vol. 34

Issue (3): 268-271 DOI: 10.19485/j.cnki.issn2096-5087.2022.03.011

疾病控制

本期目录 | 过刊浏览 | 高级检索

衡阳市成功治疗的肺结核患者5年复发影响因素分析

周旭¹, 王巧智², 万燕萍², 彭卫雄¹, 刘军¹, 黄颖¹, 徐祖辉²

1.衡阳市疾病预防控制中心,湖南衡阳 421001;
2.湖南省胸科医院,湖南长沙 410013

Factors affecting the five-year recurrence among successfully-treated pulmonary tuberculosis patients in Hengyang City

ZHOU Xu¹, WANG Qiaozhi², WAN Yanping², PENG Weixiong¹, LIU Jun¹, HUANG Ying¹, XU Zuhui²

1. Hengyang Center for Disease Control and Prevention, Hengyang, Hunan 421001, China;
2. Hunan Chest Hospital, Changsha, Hunan 410013, China

摘要
参考文献
相关文章
Metrics

全文: PDF(771 KB)
输出: BibTeX | EndNote (RIS)

摘要目的了解湖南省衡阳市肺结核患者成功治疗后5年复发情况,并分析其影响因素。方法通过结核病管理信息系统收集衡阳市2014年成功治疗的肺结核患者资料,以复发为观察终点,连续观察5年。采用Kaplan-Meier法、log-rank检验和多因素Cox比例风险回归模型分析患者复发的影响因素。结果纳入成功治疗肺结核患者6 626例,包括男性4 961例和女性1 665例,年龄中位数为54岁。5年复发536例,累计复发比例为8.09%,年均复发率为1.75/100人年。多因素Cox比例风险回归分析结果显示,男性（HR=1.592,95%CI：1.256~2.019）、≥40岁（40~<60岁,HR=7.025,95%CI：1.739~28.377;≥60岁,HR=8.175,95%CI：2.024~33.023）、农民（HR=1.379,95%CI：1.070~1.778）、复治（HR=6.398,95%CI：5.163~7.929）和病原学阳性（HR=1.255,95%CI：1.042~1.511）是成功治疗肺结核患者5年复发的危险因素。结论衡阳市肺结核患者成功治疗后5年内仍有较高的复发率。男性、40岁及以上、农民、复治和病原学阳性患者有较高的复发风险,可采取针对性干预措施。

	服务

	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	周旭
	王巧智
	万燕萍
	彭卫雄
	刘军
	黄颖
	徐祖辉

关键词 ：肺结核, 复发, 影响因素

Abstract：Objective To investigate the recurrence of pulmonary tuberculosis patients 5 years after successful treatment in Hengyang City, Hunan Province, and to analyze its influencing factors. Methods The data of pulmonary tuberculosis patients who were successfully treated in Hengyang City in 2014 were collected through the tuberculosis management information system. The recurrence of pulmonary tuberculosis was defined as the endpoint, and all patients were observed for five consecutive years. Factors affecting recurrence of pulmonary tuberculosis were identified using Kaplan-Meier estimates, log-rank test and multivariable Cox proportional hazards regression analysis. Results A total of 6 626 patients with successfully treated pulmonary tuberculosis were included, including 4 961 males and 1 665 females, with a median age of 54 years. There were 536 cases with recurrence of pulmonary tuberculosis within five years, with a 8.09% cumulative proportion of recurrence and annual recurrence rate of 1.75 per 100 person-years. Multivariable Cox proportional hazards regression analysis showed that men ( HR=1.592, 95%CI: 1.256-2.019 ), age of 40 years and greater ( age of 40 to 59 years, HR=7.025, 95%CI: 1.739-28.377; age of 60 years and greater, HR=8.175, 95%CI: 2.024-33.023), farmers ( HR=1.379, 95%CI: 1.070-1.778 ), retreatment ( HR=6.398, 95%CI: 5.163-7.929 ) and positive etiology ( HR=1.255, 95%CI: 1.042-1.511 ) were risk factors for five-year recurrence of pulmonary tuberculosis among successfully-treated patients. Conclusions High recurrence rate is found among pulmonary tuberculosis patients within five years after successful treatment in Hengyang City. There is a high risk of pulmonary tuberculosis recurrence among male, etiologically positive, retreated farmers at ages of 40 years and older, and targeted interventions are recommended.

Key words： tuberculosis recurrence influencing factors

收稿日期: 2021-08-24 修回日期: 2021-12-27 出版日期: 2022-03-10

中图分类号:

R521

基金资助:湖南省自然科学基金科卫联合项目（2018JJ6011）

通信作者: 徐祖辉,E-mail：xuzuhui@126.com

作者简介: 周旭,本科,公共卫生医师,主要从事结核病防制工作

引用本文:

周旭, 王巧智, 万燕萍, 彭卫雄, 刘军, 黄颖, 徐祖辉. 衡阳市成功治疗的肺结核患者5年复发影响因素分析[J]. 预防医学, 2022, 34(3): 268-271.
ZHOU Xu, WANG Qiaozhi, WAN Yanping, PENG Weixiong, LIU Jun, HUANG Ying, XU Zuhui. Factors affecting the five-year recurrence among successfully-treated pulmonary tuberculosis patients in Hengyang City. Preventive Medicine, 2022, 34(3): 268-271.

链接本文:

http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2022.03.011 或 http://www.zjyfyxzz.com/CN/Y2022/V34/I3/268

[1] World Health Organization.Global tuberculosis report2020[R/OL].[2021-12-27]. https://www.who.int/publications/i/item/9789240013131.pdf.
[2] FRANCISCO C,LANSANG M A,SALVANA E M,et al. Multidrug-resistant tuberculosis(MDR-TB)and multidrug-resistant HIV (MDR-HIV) syndemic:challenges in resource limited setting[J/OL]. BMJ Case Rep,2019,12(8)[2021-12-27].http://dx.doi.org/10.1136/bcr-2019-230628.
[3] JI Y,SHAO C,CUI Y,et al.18F-FDG positron-emission tomography/computed tomography findings of radiographic lesions suggesting old healed pulmonary tuberculosis and high-risk signs of predicting recurrence: a retrospective study[J]. Sci Rep,2019,9(1):12582-12584.
[4] CROFTS J P,ANDREWS N J,BARKER R D,et al.Risk factors for recurrent tuberculosis in England and Wales,1998-2005[J]. Thorax,2010,65(4):310-314.
[5] 张屹立,郑晓宇,吴悦.某市2008—2017年结核患者复发因素调查研究[J].中国医药指南,2021,19(11):121-122.
ZHANG Y L,ZHENG X Y,WU Y.Investigation and study on the recurrence factors of tuberculosis patients in a certain city from 2008 to 2017[J].Guide China Med,2021,19(11):121-122.
[6] 邱玉冰,许琳,杨蕊,等.云南省成功治疗肺结核患者5年复发情况及影响因素研究[J].预防医学,2020,32(6):559-562.
QIU Y B,XU L,YANG R,et al.Five-year recurrence rate of tuberculosis and its influencing factors among successfully treated patients in Yunnan Province[J].Prev Med,2020,32(6):559-562.
[7] World Health Organization.Definitions and reporting framework for tuberculosis-2013 revision[M]. Geneva:World Health Organization,2014.
[8] 林森林,梅建,高谦,等.结核病复发的流行病学研究进展[J].中华流行病学杂志,2013,34(4):409-412.
LIN S L,MEI J,GAO Q,et al.Recent advances in the epidemiological research on recurrent tuberculosis[J].Chin J Epidemiol,2013,34(4):409-412.
[9] 彭红,虞浩,姜洁,等.江苏省初治结核病复发流行病学特征及影响因素[J].江苏预防医学,2019,30(4):355-359.
PENG H,YU H,JIANG J,et al.Epidemiological characteristics and associated factors with tuberculosis recurrence in Jiangsu province[J].Jiangsu Prev Med,2019,30(4):355-359.
[10] LEE H,KIM J.A study on the relapse rate of tuberculosis and related factors in Korea using nationwide tuberculosis notification data[J]. Osong Public Health Res Perspect,2014,5(Suppl.):S8-S17.
[11] NEYROLLES O,QUINTANA-MURCI L. Sexual inequality in tuberculosis[J/OL]. PLoS Med,2009,6(12)[2021-12-27]. https://doi.org/10.1371/journal.pmed.1000199.
[12] SHEN X,YANG C,WU J,et al.Recurrent tuberculosis in an urban area in China:relapse or exogenous reinfection?[J].Tuberculosis,2017,103:97-104.
[13] 董振鑫,张思潮.老年涂阳肺结核患者治愈的影响因素分析[J].预防医学,2018,30(11):1142-1144.
DONG Z X,ZHANG S C.Associated factors for the cure of elderly smear-positive tuberculosis patients[J].Prev Med,2018,30(11):1142-1144.
[14] 戴志松,陈堃,林淑芳,等.福建省成功治疗的肺结核患者10年复发情况及影响因素分析[J].疾病监测,2021,36(11): 1152-1158.
DAI Z S,CHEN K,LIN S F,et al.Ten-year recurrence rate in pulmonary tuberculosis patients after successful treatment and influencing factors in Fujian[J].Dis Surveill,2021,36(11):1152-1158.
[15] 严碧涯,朱莉贞,汪钟贤,等.第1批肺结核短程化疗研究5年随访报告[J].中国防痨杂志,1993,15(4):166-168.
YAN B Y,ZHU L Z,WANG Z X,et al.Five-year follow-up report of the first batch of short-course chemotherapy studies on pulmonary tuberculosis[J].Chin J Antituberc,1993,15(4):166-168.

[1]	刘晶芝, 胡燕燕, 张学伟, 阿依努尔. 新疆阿勒泰农牧区哈萨克族小学生贫血调查[J]. 预防医学, 2023, 35(9): 807-810.
[2]	朱思懿, 洪航, 边学燕, 许国章. 慢性肾脏病流行病学研究进展[J]. 预防医学, 2023, 35(9): 770-773.
[3]	俞素芬, 蒋青林, 戴杰. 2012—2021年吴兴区新报告HIV/AIDS病例晚发现及影响因素分析[J]. 预防医学, 2023, 35(9): 796-799.
[4]	王远航, 胡洁, 葛锐, 富小飞, 亓云鹏. 嘉兴市结核分枝杆菌耐药情况分析[J]. 预防医学, 2023, 35(8): 705-709.
[5]	方柯红, 朱冰, 黄利明, 张旭慧, 刘辉. 杭州市成年居民营养健康知识调查[J]. 预防医学, 2023, 35(8): 710-713.
[6]	周星缘, 洪航, 方挺, 许国章. 肺炎流行病学研究进展[J]. 预防医学, 2023, 35(8): 682-686.
[7]	柏旭, 苏洁, 李凤, 徐倩, 沈源, 肖凌凤. 我国成人糖尿病视网膜病变影响因素的Meta分析[J]. 预防医学, 2023, 35(7): 595-601.
[8]	王梦琴, 柴荟琳, 郭宇燕, 任敬娟, 梁瑞峰. 山西省农村居民高血压防治知识、态度、行为调查[J]. 预防医学, 2023, 35(7): 563-569.
[9]	黎燕, 雷梦婷, 王燧, 殷淑娇, 章存瑞, 李清春. 一起涉及多所学校的肺结核聚集性疫情调查[J]. 预防医学, 2023, 35(7): 607-610.
[10]	彭晶, 傅文婷, 杨秀琳. 甘南藏族自治州老年人群健康素养调查[J]. 预防医学, 2023, 35(6): 546-550.
[11]	常倩, 王维丹, 钱建军, 胡华锋. 绍兴市严重精神障碍患者健康体检的影响因素分析[J]. 预防医学, 2023, 35(6): 491-495.
[12]	姜海波, 洪航, 周健, 李继革, 史宏博, 谭诗文, 褚堃, 张丹丹. 宁波市HIV/AIDS病例新型毒品使用情况调查[J]. 预防医学, 2023, 35(6): 470-474.
[13]	杨冰声, 曹承建. 杭州市美沙酮维持治疗患者脱失的影响因素分析[J]. 预防医学, 2023, 35(6): 522-525.
[14]	曾龙武, 唐晓鸿, 张素霞, 刘强, 梁朝聪, 唐漫漫. 结直肠癌化疗患者照护人疾病不确定感影响因素分析[J]. 预防医学, 2023, 35(5): 444-447.
[15]	王倩倩, 章涛, 李傅冬, 林君芬, 何凡, 俞敏, 曹亦菲. 老年人群白内障的影响因素分析[J]. 预防医学, 2023, 35(4): 311-315.

Viewed

Full text

Abstract

Cited

Shared

Discussed